Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis (Nasdaq: OCS) reported its Q4 and full year 2024 financial results, highlighting significant clinical advancements across its pipeline. The company completed an oversubscribed $100 million equity financing and reported cash position of $109 million as of December 31, 2024, providing runway into early 2028.
Key clinical developments include positive topline results from the ACUITY Phase 2 trial of Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial of Licaminlimab (OCS-02) in dry eye disease. The company is on track to complete enrollment for Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema.
Financial highlights:
- Q4 2024 net loss: $32.6 million vs $14.1 million in Q4 2023
- FY2024 net loss: $97.4 million vs $98.8 million in 2023
- R&D expenses increased to $59.1 million in 2024 from $32.6 million in 2023
- G&A expenses rose to $24.8 million in 2024 from $19.5 million in 2023
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's Chief Financial Officer, Sylvia Cheung, will present on March 11, 2025, at 3:00pm ET in Miami Beach, FL. Investors can request one-on-one meetings through their institutional representatives.
A live webcast of the fireside chat will be accessible through the Events and Presentations section of the Oculis website under Investors & Media.
Oculis (OCS) announced the vesting and settlement of previously granted Restricted Stock Units (RSUs) for company directors. The transactions specifically involve directors Anthony Rosenberg and Arshad Khanani, as reported in notifications filed in March 2025.
Oculis Holding AG (Nasdaq: OCS) has announced the pricing of an oversubscribed offering of 5,000,000 ordinary shares at $20.00 per share, raising total gross proceeds of $100 million. The offering is expected to close around February 18, 2025.
The new shares will be issued from the Company's existing capital band, increasing the total authorized registered shares to 53,943,700. The proceeds will be used to advance and accelerate Oculis' clinical development pipeline, particularly the development of its novel neuroprotective candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.
BofA Securities and Leerink Partners are serving as joint bookrunning managers, with Pareto Securities as lead manager and Arctica Finance as financial advisor for the offering.
Oculis Holding AG (Nasdaq: OCS) has announced the pricing of an oversubscribed offering of 5,000,000 ordinary shares at $20.00 per share, raising total gross proceeds of $100 million. The offering is expected to close around February 18, 2025.
The new shares will be issued from the company's existing capital band, bringing total authorized registered shares to 53,943,700. The proceeds will be used to advance and accelerate Oculis's clinical development pipeline, particularly the development of its novel neuroprotective candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.
BofA Securities and Leerink Partners are serving as joint bookrunning managers, with Pareto Securities as lead manager and Arctica Finance as financial advisor for the offering.
On February 8, 2025, Oculis, based in Zug, Switzerland, announced notifications regarding transactions involving earnout shares for several persons discharging managerial responsibilities. The notifications specifically detail the vesting of earnout shares and the removal of restrictions on ordinary shares. The transactions involve four individuals: Anthony Rosenberg, Pall Johanesson, Riad Sherif, and Sylvia Cheung.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) has issued 2,500,000 new registered ordinary shares with a nominal value of CHF 0.01 each from its existing capital band. These shares are currently recorded as treasury shares. The company's total registered shares now stand at 48,943,700, with approximately 43 million shares outstanding. Following this issuance, treasury shares represent 7.2% of the company's registered shares.
The new shares were issued in connection with an at-the-market (ATM) offering program established through a sales agreement with Leerink Partners on May 8, 2024. Under this program, Oculis may offer and sell ordinary shares worth up to $100 million through Leerink Partners as its sales agent. The newly issued shares have not been sold under the ATM program and are being held in reserve as treasury shares.
In a brief announcement dated January 21, 2025, Oculis, based in Zug, Switzerland, has disclosed a notification regarding major changes in voting rights. The changes involve Íslandsbanki, though specific details about the nature and extent of these changes were not provided in the announcement.
On January 20, 2025, Oculis announced the publication of a Notification of Major Changes in Voting Rights in Zug, Switzerland. The notification specifically relates to changes involving Íslandsbanki. No further details about the nature or extent of the voting rights changes were provided in the announcement.
Oculis announced positive topline results from its Phase 2 ACUITY trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic neuritis. The trial met its primary safety endpoint and achieved statistical significance on key efficacy endpoints.
The randomized, double-blind study evaluated 33 patients receiving OCS-05 (2mg/kg/day or 3mg/kg/day) administered intravenously for five days. Key results include:
- 43% improvement in GCIPL thickness at 3 months for OCS-05 (3mg/kg/day)
- 28-30% improvement in RNFL thickness at 3-6 months
- Approximately 18 letters improvement in visual function at 3 months
The treatment showed a favorable safety profile with no serious adverse events or discontinuations. The FDA has granted orphan drug designation and cleared the IND application, enabling U.S. clinical development. The company reports approximately $105-110 million in cash and equivalents.
FAQ
What is the current stock price of Oculis Holding (OCS)?
What is the market cap of Oculis Holding (OCS)?
